Sangamo Therapeutics has higher earnings, but lower revenue than Novavax. Novavax is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The firm has a market cap of $223.26 million, a price-to-earnings ratio of -1.43 and a beta of 1.30. About Sangamo ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data, following a pattern of big pharma partners ending collaborations. Current hemophilia A market ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

Truist Financial analyst Nicole Germino maintained a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of ...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to ...